CHAI Biomarker
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Key Facts
About Valar Labs
Valar Labs is a private, clinical-stage diagnostics company leveraging a proprietary AI platform to interpret standard histology slides and predict treatment response in oncology. Its lead product, Vesta, is positioned as the first AI diagnostic to predict response to BCG therapy in bladder cancer. The company, backed by a $22 million Series A from investors like DCVC and a16z, partners with pharmaceutical companies for biomarker discovery and aims to expand its predictive assays into other cancer types such as prostate and pancreatic cancer.
View full company profileAbout Valar Labs
Valar Labs is a private, clinical-stage diagnostics company leveraging a proprietary AI platform to interpret standard histology slides and predict treatment response in oncology. Its lead product, Vesta, is positioned as the first AI diagnostic to predict response to BCG therapy in bladder cancer. The company, backed by a $22 million Series A from investors like DCVC and a16z, partners with pharmaceutical companies for biomarker discovery and aims to expand its predictive assays into other cancer types such as prostate and pancreatic cancer.
View full company profileTherapeutic Areas
Other Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Decipher Prostate | Decipher Biosciences | Launch |
| Nubeqa® (darolutamide) | Bayer | Phase III |